title: Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
authors.forename: Mikkel
authors.initials: M
authors.lastname: Christensen
authors.forename: Filip K
authors.initials: FK
authors.lastname: Knop
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069476:Linagliptin; D008687:Metformin / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D013453:Sulfonylurea Compounds; D000069476:Linagliptin; C057619:glimepiride; D008687:Metformin